

Special Issue

Breaking through the Barricades: Immune Checkpoint Molecules and Immunotherapy in Cancer

Message from the Guest Editor

This Special Issue will focus on emerging trends in immune checkpoint molecules and immunotherapy in cancer. Although the use of PD-1/PD-L1 and CTLA-4 inhibitors yields unprecedented clinical effects, the role of ICIs in the modulation of the crosstalk between cancer cells and other tumor-associated cell types (e.g., immune and vascular cells) is another key feature that still has not been deeply investigated. The discovery of these mechanisms has the potential to give rise to the development of new therapeutic strategies, and to the development of new prognostic and predictive biomarkers. This Special Issue invites submissions in any area relating to these themes. Possible topics within this scope include (but are not limited to) the following:

- Identification of novel immune checkpoints and inhibitors;
- Molecular mechanisms regulating immune checkpoint molecule expression;
- Mechanisms of resistance to ICIs;
- Strategies to improve the efficacy of ICIs;
- Impact of ICIs on tumor angiogenesis and lymphangiogenesis;
- Mechanisms of tumor cell invasion and metastatic dissemination;
- Evaluation of new biomarkers with predictive value for ICI therapies.

Guest Editor

Dr. Eva Andreuzzi

Department of Research and Diagnosis, Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/117578

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).